Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc., is pleased to announce that it has initiated a new program whose goal is to identify and develop novel, safe agents that promote neuroplasticity without the liabilities of abuse potential or hallucinations that occur with psychedelics which include ketamine, LSD and tryptamine derivatives such as DMT and psilocybin.
Category Press Release